What is a Biological Medicine and When Does it Appear in Claims?
Understanding biologics, their role in treating chronic conditions, and what you need to assess in insurance claims.
Published: 3 April 2026 | Updated: 3 April 2026
What is a Biological Medicine?
A biological medicine (or biologic) is a drug made from living organisms or their components. Rather than being synthesised through chemistry like conventional tablets and capsules, biologics are manufactured using biotechnology: living cells are engineered to produce the active ingredient. Think of it as a pharmaceutical product grown in a bioreactor rather than mixed in a vat.
Common biological medicines include monoclonal antibodies (which target specific immune pathways), growth factors, hormones produced by genetic engineering, and vaccines. Examples you'll encounter in claims include infliximab for inflammatory conditions, insulin for diabetes, and various cancer immunotherapies. These drugs are typically delivered by injection or infusion and are significantly more expensive than conventional medicines.
How Do Biologics Differ from Conventional Medicines?
| Feature | Conventional Drug | Biological Medicine |
|---|---|---|
| Manufacturing | Chemical synthesis in laboratory | Living cells engineered to produce it |
| Molecular size | Small, simple molecules | Large, complex proteins |
| Stability | Stable, long shelf-life | Temperature-sensitive, requires cold storage |
| Cost | Low to moderate | Very high (AUD/NZD 1,000s per dose) |
| Generic copies | Possible after patent expires | Biosimilars possible, but more complex |
| Administration | Typically oral (tablet/capsule) | Usually injection or infusion |
Why Do Biologics Appear in Insurance Claims?
Biologics are typically prescribed for serious, chronic conditions where conventional treatments have failed or are inadequate. In claims, you'll most often see them for conditions like rheumatoid arthritis, Crohn's disease, certain cancers, multiple sclerosis, and severe psoriasis. They're prescribed because they work by targeting specific disease mechanisms, offering better outcomes than traditional drugs for conditions that are resistant to conventional therapy.
Common Clinical Scenarios in Claims
- Post-injury inflammatory conditions: A claimant develops chronic inflammatory conditions following workplace injury and has not responded to conventional anti-inflammatories.
- Cancer treatment: Oncologists prescribe immunotherapy biologics as part of cancer management arising from a compensable condition.
- Chronic pain with immune involvement: Some claimants with complex regional pain syndrome or other neuropathic conditions have been prescribed biologics targeting immune pathways.
- Management of secondary autoimmune conditions: Claimants develop autoimmune disease secondary to their primary injury and require biological therapy.
- Diabetes management: Claimants with diabetes (pre-existing or injury-related) may be prescribed biologic insulin or GLP-1 agonists.
What Should You Assess in a Biologic Claim?
Step 1: Confirm the Clinical Indication
Is the biologic approved for the condition being treated? What is the documented clinical diagnosis, and does the prescription match that diagnosis? Biologics are often prescribed off-label, which isn't necessarily wrong, but it requires clear documentation of why.
Step 2: Verify Treatment Failure
Has the claimant tried appropriate conventional treatments first and failed to respond? Most clinical guidelines recommend conventional therapy before biologics. Your claim handler should seek evidence that conventional options were adequately trialled and documented as ineffective.
Step 3: Check for Monitoring and Response
Is the claimant being monitored for response? Biologics work for some patients and not others. If the patient isn't responding after a reasonable period, continuing the expensive treatment is unjustified. Request regular clinical progress notes.
Step 4: Assess Connection to the Insured Event
Is the condition for which the biologic is prescribed connected to the original injury or event being claimed? This is essential for workers compensation and CTP claims. A long-standing autoimmune condition unrelated to the injury is not your insurer's responsibility.
Red Flags in Biologic Medication Claims
- Biologic prescribed without documented evidence of failure of conventional treatments.
- No baseline clinical assessment or regular monitoring to assess response.
- The condition for which the biologic is prescribed appears unrelated to the compensable injury.
- Continuation of biologic despite documented lack of response or deteriorating condition.
- Prescriber is not a specialist appropriately trained in prescribing that particular biologic.
- Multiple biologics prescribed simultaneously without clear clinical rationale.
- No documented discussion of cost or consideration of alternative therapies.
Biosimilars and Cost Control
When a biologic patent expires, manufacturers can produce "biosimilars": medicines that are very similar to the original biologic but not identical (unlike conventional generic drugs). Biosimilars are typically 20-40 percent cheaper than the originator biologic. In both Australia and New Zealand, regulators have approved biosimilars for many common biologics.
Your insurer should encourage transition to biosimilars where clinically appropriate. A patient stable on an originator biologic who could switch to a cheaper biosimilar without clinical risk should do so. This is a legitimate cost-control measure and is increasingly standard practice in health systems.
Jurisdiction-Specific Considerations
In Australia, the TGA approves all biologics, and the Pharmaceutical Benefits Scheme (PBS) lists those eligible for government subsidy. Private insurers generally must cover PBS-listed biologics if clinically indicated, but they can assess whether clinical indications are met. In New Zealand, Medsafe approves biologics, and PHARMAC manages the public subsidy scheme. Both countries have similar regulatory standards, so a biologic approved in one is typically approved in the other, though PBS and PHARMAC listings may differ.
Key Questions for Your Pharmacist
When you refer a biologic claim for medication review, ask your pharmacist to address these points:
- Is this biologic appropriate for the documented clinical condition?
- Has the claimant adequately trialled conventional treatments first?
- Is there documented clinical response to the biologic?
- Is the condition related to the compensable injury?
- Is a biosimilar available, and would switching be clinically safe?
- What is the ongoing clinical rationale for continuation?
- Are there any safety concerns or adverse effects that should be monitored?
Summary: Your Decision Framework
Biologic medications are legitimate in claims when used appropriately: for serious conditions inadequately controlled by conventional therapy, with documented clinical indication and response, and with regular monitoring to ensure continued need. They're expensive, so your insurer should carefully assess whether all these criteria are met. Many biologics are appropriate and cost-effective in the long term; your role is to ensure they're used for the right patients, monitored properly, and transitioned to cheaper alternatives (such as biosimilars) where clinically safe to do so.
Unsure about a biologic claim?
IMM's pharmacists assess biologic use in insurance claims, checking clinical appropriateness, response, and whether transitioning to cost-effective alternatives like biosimilars is safe. We help insurers manage these expensive medications effectively without compromising claimant outcomes.
Request a Medication Review
